C

Cannara Biotech Inc
XTSX:LOVE

Watchlist Manager
Cannara Biotech Inc
XTSX:LOVE
Watchlist
Price: 1.69 CAD 1.2% Market Closed
Market Cap: 160.4m CAD

Relative Value

The Relative Value of one LOVE stock under the Base Case scenario is hidden CAD. Compared to the current market price of 1.69 CAD, Cannara Biotech Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LOVE Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
65
vs Industry
63
Median 3Y
1.4
Median 5Y
1.7
Industry
2.6
Forward
1.3
vs History
52
vs Industry
26
Median 3Y
12
Median 5Y
11.9
Industry
21.7
Forward
10.1
vs History
34
vs Industry
42
Median 3Y
6.3
Median 5Y
5.4
Industry
16.6
vs History
31
vs Industry
21
Median 3Y
14.7
Median 5Y
-5.6
Industry
22.5
vs History
42
vs Industry
51
Median 3Y
1.1
Median 5Y
1.4
Industry
2.3
vs History
74
vs Industry
54
Median 3Y
1.7
Median 5Y
2.5
Industry
2.9
Forward
1.4
vs History
96
vs Industry
9
Median 3Y
17.8
Median 5Y
20
Industry
5.5
vs History
vs Industry
21
Median 3Y
-30.2
Median 5Y
-46.1
Industry
13.1
Forward
5.1
vs History
vs Industry
7
Median 3Y
-13.3
Median 5Y
-18.3
Industry
16.6
Forward
6.2
vs History
44
vs Industry
39
Median 3Y
9.2
Median 5Y
7.6
Industry
15.8
vs History
26
vs Industry
27
Median 3Y
9.6
Median 5Y
-4.3
Industry
19.1
vs History
47
vs Industry
53
Median 3Y
1
Median 5Y
1.2
Industry
1.9

Multiples Across Competitors

LOVE Competitors Multiples
Cannara Biotech Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Cannara Biotech Inc
XTSX:LOVE
154.5m CAD 1.4 11.8 -150.6 -22.3
US
Eli Lilly and Co
NYSE:LLY
955.6B USD 16.1 51.9 34.9 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.9B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
247.6B CHF 4 26.3 11.3 13.1
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.8 29.9 108.2 158.4
CH
Novartis AG
SIX:NOVN
205.5B CHF 4.6 17.8 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
248B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.2 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
148B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
CA
C
Cannara Biotech Inc
XTSX:LOVE
Average P/E: 22
11.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.3
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
C
Cannara Biotech Inc
XTSX:LOVE
Average EV/EBITDA: 437.5
Negative Multiple: -150.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.3
4%
2.8
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
C
Cannara Biotech Inc
XTSX:LOVE
Average EV/EBIT: 1 878.4
Negative Multiple: -22.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3